ALT · Company research
Altimmune, Inc. (ALT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| TRALUCENT GLOBAL ALT (LONG/SHOR (TGAF.NE) interactive stock chart - Yahoo Finance UK | TRALUCENT GLOBAL ALT (LONG/SHOR (TGAF.NE) interactive stock chart Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| TRALUCENT GLOBAL ALT (LONG/SHOR (TGAF.NE) stock price, news, quote and history - Yahoo Finance Australia | TRALUCENT GLOBAL ALT (LONG/SHOR (TGAF.NE) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 11, 2026 | neutral | 0 | 0.6 |
| Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT) - The Globe and Mail | Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT) The Globe and Mail | View source ↗ | The Globe and Mail | Oct 10, 2026 | neutral | 0 | 0.6 |
| ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits | ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Stocktwits | Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| 4621074.IR Purchase Info | Investment Information for ALT WHITE A/USD Stock - Yahoo! Finance Canada | 4621074.IR Purchase Info | Investment Information for ALT WHITE A/USD Stock Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? | Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? | Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| CFO surrenders 4,379 shares in Altimmune (ALT) solely to cover stock-vesting taxes. - Stock Titan | CFO surrenders 4,379 shares in Altimmune (ALT) solely to cover stock-vesting taxes. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| ALT Oct 2026 3.500 call (ALT261016C00003500) Stock Price, News, Quote & History - Yahoo! Finance Canada | ALT Oct 2026 3.500 call (ALT261016C00003500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 4, 2026 | neutral | 0 | 0.6 |
| Altimmune (NasdaqGM:ALT) Stock Forecast & Analyst Predictions - Simply Wall Street | Altimmune (NasdaqGM:ALT) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 23, 2026 | neutral | 0 | 0.6 |
| Altimmune (ALT) exec gains stock as 24,000 RSUs vest - Stock Titan | Altimmune (ALT) exec gains stock as 24,000 RSUs vest Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Yahoo Finance | Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 11, 2026 | neutral | 0 | 0.6 |
| $ALT stock is up 7% today. Here's what we see in our data. - Quiver Quantitative | $ALT stock is up 7% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 21, 2026 | neutral | 0 | 0.6 |
| Altimmune Reports $22.8 Million Q2 Loss and Advances Pemvidutide Trials | ALT Stock News - Quiver Quantitative | Altimmune Reports $22.8 Million Q2 Loss and Advances Pemvidutide Trials | ALT Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| Altimmune to discuss its liver-treatment candidate Aug. 12 - Stock Titan | Altimmune to discuss its liver-treatment candidate Aug. 12 Stock Titan | View source ↗ | Stock Titan | Aug 5, 2026 | neutral | 0 | 0.6 |
| ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - Stocktwits | ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff Stocktwits | View source ↗ | Stocktwits | Jul 28, 2026 | neutral | 0 | 0.6 |
| Altimmune rises as GLP-1 cuts drinking in mid-stage trial - Seeking Alpha | Altimmune rises as GLP-1 cuts drinking in mid-stage trial Seeking Alpha | View source ↗ | Seeking Alpha | Jul 28, 2026 | neutral | 0 | 0.6 |
| Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? - Yahoo Finance | Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 12, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.